Overview
Extension Study of MT-1303 in Subjects With Crohn's Disease
Status:
Completed
Completed
Trial end date:
2017-08-01
2017-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objectives of the study are: -To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Criteria
Inclusion Criteria:- The subject completed 14 week Treatment Period in the double blind MT-1303-E13 study
as per Protocol.
Exclusion Criteria:
- Permanent discontinuation of study medication prior to the end of treatment Visit in
MT-1303-E13